Tipsheet
What matters at India’s listed companies
Brief /Earnings / Life Sciences Consumables

Tarsons Products profit drops 52% as finance and depreciation costs bite

Revenue crept higher while bottom-line profitability collapsed. The company also disclosed an unauthorised ₹4.1 cr payout to its top directors.

2 earlier stories on Tarsons Products Ltd.
Mkt cap₹1,163 cr
P/E35.35×
ROE4.72%
Debt / eq.0.52
₹14.3 cr Consolidated net profit for FY26, a 52% drop from the prior year.

What's new with Tarsons Products Ltd.

  • Consolidated net profit fell to ₹14.3 cr from ₹29.8 cr last year.
  • Finance costs reached ₹22.5 cr and depreciation hit ₹96.5 cr.
  • Management paid itself ₹4.1 cr in excess remuneration requiring a shareholder waiver.

Why this matters for Tarsons Products Ltd.

The gap between top-line growth and bottom-line erosion is stark. The excess remuneration disclosure suggests poor internal controls on executive pay at a time when shareholders are already seeing profit margins sliced in half.

What we're watching

  • Whether shareholders approve the waiver for the excess executive pay.
  • If the high depreciation cost trajectory from the new facilities moderates in FY27.
  • The recovery timeline for margins.

The full read

Tarsons Products ended FY26 with a painful disconnect between sales and earnings. While revenue managed a modest 7.7% lift to ₹422.5 crore on the back of domestic demand, the profit line collapsed. Consolidated net profit fell 52% to ₹14.3 crore, dragged down by heavy non-operating charges. Finance costs grew to ₹22.5 crore, and depreciation climbed to ₹96.5 crore, reflecting the burden of recent capital investments. The company further complicated its narrative by disclosing ₹4.1 crore in excess remuneration paid to its managing director and whole-time director. Tarsons must now solicit a shareholder waiver for these payments. Investors are left with a company that is growing its footprint but struggling to convert that scale into cash, all while needing to clean up a governance oversight regarding executive compensation.

Mentioned: Tarsons Products · Grant Thornton Bharat · ₹4.1 cr excess remuneration
Primary source BSE · NSE · Tijori

Our reading of the company's own disclosure. Always confirm against the original source.